Olmutinib

HCID 54758501

노트 반응

부분 구조 검색 유사 구조 찾기

기본 정보

CAS: 1353550-13-6
표준 SMILES: C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc3ccsc23)c1
InChIKey: FDMQDKQUTRLUBU-UHFFFAOYSA-N
분자식: C26H26N6O2S
평균 분자량: 486.6 g/mol
단동위원소 질량: 486.18379527

이름 및 식별자

우선 이름: Olmutinib
IUPAC: N-[3-[2-[4-(4-methylpiperazin-1-yl)anilino]thieno[3,2-d]pyrimidin-4-yl]oxyphenyl]prop-2-enamide
영어명: HM-61713 (BI-1482694)
분자량: 0

이름 및 동의어

Olmutinib1353550-13-6BI 1482694HM-61713BI-1482694CHL9B67L95N-[3-[2-[4-(4-methylpiperazin-1-yl)anilino]thieno[3,2-d]pyrimidin-4-yl]oxyphenyl]prop-2-enamide2-Propenamide, N-[3-[[2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]thieno[3,2-d]pyrimidin-4-yl]oxy]phenyl]-DTXSID0013191192-Propenamide, N-(3-((2-((4-(4-methyl-1-piperazinyl)phenyl)amino)thieno(3,2-d)pyrimidin-4-yl)oxy)phenyl)-N-{3-[(2-{[4-(4-methylpiperazin-1-yl)phenyl]amino}thieno[3,2-d]pyrimidin-4-yl)oxy]phenyl}prop-2-enamideN-(3-((2-(4-(4-Methylpiperazin-1-yl)anilino)thieno(3,2-d)pyrimidin-4-yl)oxy)phenyl)prop-2-enamide

이름 더 보기

HM-61713 (BI-1482694)NSC 163501ANTIBIOTIC AT-125U 42126HM 61713HM61713BI1482694

N-[3-({2-[4-(4-Methylpiperazin-1-yl)anilino]thieno[3,2-d]pyrimidin-4-yl}oxy)phenyl]prop-2-enamideolmutinibumN-(3-((2-((4-(4-methylpiperazin-1-yl)phenyl)amino)thieno(3,2-d)pyrimidin-4-yl)oxy)phenyl)prop-2-enamideN-(3-(2-(4-(4-methylpiperazin-1-yl)anilino)thieno(3,2-d)pyrimidin-4-yl)oxyphenyl)prop-2-enamideRefChem:856756L01XE40DTXCID4017485501802181-20-9

데이터베이스 식별자

CAS: 1353550-13-6、1802181-20-9
PubChem CID: 54758501
DTXSID: DTXSID001319119
ChEMBL: CHEMBL3786343
UNII: CHL9B67L95
Nikkaji: J3.435.413H

물성

구조 계산 물성

XLogP: 4.7
극성 표면적: 111 Å²
수소 결합 공여자 수: 2
수소 결합 수용자 수: 8
회전 가능 결합 수: 7
무거운 원자 수: 35
형식 전하: 0
복잡도: 712

화학 및 산업

약리 정보

ATC Code · 2건

L - Antineoplastic and immunomodulating agents；L01 - Antineoplastic agents；L01E - Protein kinase inhibitors；L01EB - Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors；L01EB06 - Olmutinib

QL - Antineoplastic and immunomodulating agents；QL01 - Antineoplastic agents；QL01E - Protein kinase inhibitors；QL01EB - Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors；QL01EB06 - Olmutinib

Protein BindingData not yet available.

Pharmacodynamics · 1건

Olmutinib selectively and irreversibly binds and inhibits epidermal growth factor receptors (EGFR) with the T790M activating mutation. EGFRs are frequently over-expressed in lung cancer and contribute to activation of the phosphoinositide 3-kinase and mitogen activated protein kinase pathways which both promote cell survival and proliferation. By inhibiting EGFR activation, olmutinib attenuates the activation of these tumor promoting pathways.

Mechanism of Action · 1건

Olmutinib covalently binds a cysteine residue near the kinase domain of mutant EGFRs to prevent phosphorylation of the receptor. This inhibits receptor signalling as phosphorylation is necessary for recruitment of signalling cascade proteins.

Biological Half-Life8-11h.

Metabolism/MetabolitesData not yet available.

공급사100 곳

陕西缔都医药有限责任公司029-81124775 17791530730 · [email protected]

南通飞宇生物科技有限公司0513-68819626 15152877458 · [email protected]

武汉英诺医药科技有限公司+86-027-59232304 15387063101 · [email protected]

苏州景皓生物科技有限公司18136139868; 18136139868

上海麦克林生化科技股份有限公司021-50706066 15221275939 · [email protected]

화합물 노트

불러오는 중…